<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665119</url>
  </required_header>
  <id_info>
    <org_study_id>FP-TIP-01</org_study_id>
    <nct_id>NCT00665119</nct_id>
  </id_info>
  <brief_title>Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients</brief_title>
  <official_title>Effects of Remifentanil on Breathing Pattern, Respiratory Effort and Gas Exchange in Mechanically Ventilated Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Poliambulanza Istituto Ospedaliero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Poliambulanza Istituto Ospedaliero</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sedation is widely used in mechanically ventilated patients. Propofol, benzodiazepines and
      opioids are the most used drugs. The study hypothesis is that sedation with remifentanil (an
      opioid drug) could improved respiratory pattern and effort in mechanically ventilated
      patients with rapid shallow breathing or high respiratory rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory rate/tidal volume</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pressure-time product</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>double product of respiratory system</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dynamic intrinsic PEEP</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during all the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pH</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of sedation (RASS)</measure>
    <time_frame>before and after remifentanil infusion; before and after placebo infusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <condition>Respiration, Artificial</condition>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>NaCl 0.9 %</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pressure support ventilation or CPAP

          -  respiratory rate &gt; 35.min-1

          -  respiratory rate/tidal volume &gt; 105

        Exclusion Criteria:

          -  vasoactive agents (dopamine lower than 5 mcg.kg-1.min-1 is not considered as
             vasoactive agent)

          -  body temperature &gt; 38 Â°C

          -  Glasgow Coma Scale &lt; 9

          -  FIO2 &gt; 0.6

          -  PEEP &gt; 10 cmH2O

          -  pH &lt; 7.30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Natalini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Poliambulanza Istituto Ospedaliero</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Care Unit, Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Natalini Giuseppe</name_title>
    <organization>FPoliambulanza</organization>
  </responsible_party>
  <keyword>Respiratory Insufficiency</keyword>
  <keyword>Respiration, Artificial</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Respiratory Mechanics</keyword>
  <keyword>Work of Breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

